logo

Aridis Pharmaceuticals Inc (ARDS)



Trade ARDS now with
  Date
  Headline
9/8/2020 5:39:37 AM Aridis Reaches Agreement With FDA To Simplify AR-501 Phase 2 Trial Design
6/22/2020 5:34:21 AM Aridis Announces Positive Results From Phase 1 Portion Of Phase 1/2a Clinical Trial Of AR-501
6/15/2020 5:36:01 AM Aridis Pharmaceuticals Appoints Hasan Jafri As Chief Medical Officer
5/4/2020 5:47:27 AM Aridis Pharma Enrolls First COVID-19 Patient In Ongoing Phase 3 AR-301 Clinical Trial In Ventilator Associated Pneumonia
4/8/2020 5:04:51 PM Aridis Pharmaceuticals Q4 Loss/share $0.63 Vs. Loss $0.67 Year Ago
1/2/2020 5:32:38 AM Aridis Pharma Appoints Michael Nazak As CFO, Effective January 1
11/13/2019 4:12:52 PM Aridis Pharma Q3 Loss/share $0.87 Vs. Loss $1.97 Year Ago
10/11/2019 5:34:52 AM Aridis Appoints Paul Mendelman As Interim Chief Medical Officer
9/30/2019 5:51:44 AM Aridis Says Consummated Licensing Agreement With Serum AMR
9/3/2019 5:33:23 AM Aridis Says Phase 2 Clinical Trial Evaluating AR-105 Did Not Meet Its Primary Endpoint
9/3/2019 5:32:18 AM Aridis Announces Results From First-in-patient Phase 2 Clinical Trial Evaluating AR-105